Sustainability goals
Camurus’ sustainability goals are grounded in our sustainability agenda, which is structured around four focus areas: Patients, People, Planet, and Responsible Business. These goals are informed by a comprehensive materiality analysis and ongoing stakeholder dialogue, ensuring that we focus on the most relevant and impactful areas of sustainability.
Focus area
Patients
- NEW - From 2025: Ensure and enhance engagement in disease awareness activities for approved medication and late-stage candidates
- By 2026: Take at least one new drug to regulatory approval
- UPDATED - By 2027: Enhance access to evidence-based treatments for opioid dependence, increase number of patients in treatment on Buvidal to > 100,000
- NEW - By 2030: Obtain regulatory approvals for CAM2029 in two new indications
Focus area
People
- NEW - From 2025: Maintain a high degree of inclusion amongst Camurus’ employees by reaching a score equal to or above 8 in the relevant categories in the annual regular employee survey
- By 2026: Healthy work attendance over 97%
- By 2026: Gender distribution at Board and management level must reflect the company as a whole (±20%)
Focus area
Planet
- Transition from combustion engine cars to electric cars should be conducted as fast as possible1: From 2024 all new benefit cars are electric cars; Transition of job cars to electric cars in the Nordic countries by 2030; Transition of job cars to electric cars in other European countries by 2035; Transition of job cars to electric cars in all other countries by 2040
- From 2024: At least 80% of the energy used within Camurus’ operations to come from renewable sources
- By 2035: Reduce scope 1 and 22 greenhouse gas emissions by at least 50%3
- By 2035: Reduce selected scope 34 greenhouse gas emissions by at least 40%3
- By 2045: Net zero greenhouse gas emissions (scope 1, 2 and 3)5
Focus area
Responsible business
- By 2026: Annual training of all Camurus employees and consultants in the company's Code of Conduct in relevant topics, such as anti-corruption and data protection
- By 2026: Ensure an open culture where employees feel safe to report suspected misconduct, including corruption, as well as a robust framework for monitoring within which any problems are identified and addressed
- By 2026: Disclose value transfers to the healthcare system according to applicable industry codes or on a voluntary basis, see transparency reporting
- By 2026: Monitor all suppliers in the first tier within research and development, production and distribution regarding compliance with Camurus’ Vendor Code of Conduct
- NEW - From 2027: Perform compliance and sustainability review/audit and implement mitigating actions as needed on "high risk" Third Parties Intermediaries and "high risk" significant vendors every 3 years.
- NEW - From 2027: Perform independent evaluation of Camurus' Business Ethics and Compliance framework every 2 years. Achieve overall rating result for maturity at a minimum level 3 on a scale 1-5.
References
- Where technically feasible.
- Scope 1 emissions include direct emissions from owned or controlled sources. Scope 2 emissions include indirect emissions from the generation of purchased energy.
- Compared to 2023.
- Scope 3 emissions include all indirect emissions (excluding scope 2) that occur in the company's supply chain, both upstream and downstream.
- The remaining greenhouse gas emissions that cannot be reduced will be offset in 2045 and beyond.